Human Immunodeficiency Virus (HIV) Therapeutics Market Analysis

Human Immunodeficiency Virus Therapeutics Market Analysis

Based on drug type, the market is segmented into branded drugs and generic drugs. Branded drugs dominate the market with a share of 74.5% in 2024.
 

• Increasing prescriptions for fixed dose combinations such as Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide), Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide), and Triumeq (abacavir, dolutegravir, and lamivudine) are contributing to the revenue growth in the segment. These drugs have proven effectiveness, long-standing clinical use, and their role in combination therapies offer convenient dosing and improved patient outcomes, as a result, their prescriptions have surged.
   
• Additionally, branded drugs, particularly those from newer classes like integrase inhibitors often offer superior efficacy and safety profiles compared to older therapies, further contributing to the increasing prescriptions for branded drugs.
   
• Moreover, drug manufacturers are frequently introducing new formulations or combination therapies, merging multiple antiretroviral drugs into a single pill. This approach has streamlined the treatment regimens and enhanced the patient adherence, contributing to the revenue growth in branded drugs segment.
   

Based on drug class, the human immunodeficiency virus therapeutics market is segmented into nucleoside-analog reverse transcriptase inhibitors, integrase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, entry and fusion inhibitors, and coreceptor antagonists. The nucleoside-analog reverse transcriptase inhibitors segment held a dominating share of 41.2% in the market in 2024.
 

• Nucleoside-analog reverse transcriptase inhibitors represent one of the most established and widely utilized classes of HIV medications. Their extensive clinical application has demonstrated their effectiveness in inhibiting the reverse transcriptase enzyme, essential for HIV replication. Key nucleoside-analog reverse transcriptase inhibitors, such as lamivudine, zidovudine, and tenofovir, are integral to combination therapies, particularly in first-line treatment regimens.
   
• Moreover, nucleoside-analog reverse transcriptase inhibitors, including tenofovir, are integral to PrEP for HIV-negative individuals, significantly reducing infection risk. Their dual application in both treatment and prevention enhances their market impact and contributes to their dominating share.
   

Based on distribution channel, the HIV therapeutics market is segmented into hospital pharmacies, drugs stores and retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market with a share of about 47.4% in the year 2024.
 

• Hospital pharmacies provide a more extensive range of specialized human immunodeficiency virus medications, including injectables and newer antiretrovirals, which are not yet widely available at retail pharmacies. This range includes long-acting injectable therapies and combination treatments that require precise administration under medical supervision.
   
• Patients with advanced HIV stages or complex treatment histories, such as drug resistance, typically receive care in hospitals. These individuals require intensive treatment, making hospital settings more suitable than local pharmacies. As a result, hospital pharmacies handle a higher volume of specialized HIV medication prescriptions.
   

In 2024, the U.S. led the North American HIV therapeutics market, generating a revenue of about USD 14.5 billion.
 

• According to recent data from the Centers for Disease Control and Prevention (CDC), approximately 31,800 people received an HIV diagnosis in the United States in 2022. The 12% drop in HIV infections from 2018 to 2022 can likely be attributed to heightened prescriptions of PrEP, increased rates of viral suppression, and expanded HIV testing. The increasing prescriptions of PrEP therapeutics are driving the revenue growth in the U.S.
   
• Moreover, the U.S. has one of the most developed healthcare systems in the world, with a high level of access to specialized care for people living with HIV. This includes access to the latest antiretroviral therapies (ART), clinical trials, and innovative treatments, such as long acting injectables.
   
• Furthermore, in the U.S., there is a relatively high level of access to health insurance (especially with government programs like Medicaid and Medicare), ensuring that more patients can access lifesaving HIV treatments. The presence of a robust retail pharmacy network, hospital pharmacies, and online platforms further supports the availability of treatments across the country?, contributing to the revenue growth.
   

The UK is set to see a robust expansion in its human immunodeficiency virus therapeutics market from 2025 to 2034.
 

• Favorable support from government initiatives and public health campaigns is driving awareness, reducing the stigma, and is promoting regular testing for HIV infections in the UK. For example, the British HIV Association (BHIVA) plays an essential role in educating both healthcare providers and the general public about HIV, helping to maintain high levels of early diagnosis and treatment adherence?.
   
• Further, patients in the UK are among the quick adopters of the latest HIV therapies, including long-acting injectables and fixed-dose combinations. The easy availability of these newer therapies has ensured that people living with HIV in the UK have access to the most effective treatments to improves adherence and viral suppression rates. Easy availability and growing adoption for new treatment regimens is contributing to the revenue growth in the UK.
   

Japan's human immunodeficiency virus therapeutics market is set for lucrative growth from 2024 to 2034.
 

• The Japanese government's prioritization of HIV/AIDS prevention and treatment within its public health initiatives has significantly impacted market dynamics. Programs such as free HIV testing (part of National AIDS Prevention Program) and the provision of antiretroviral therapy at no cost to residents have effectively reduced HIV transmission rates. These measures have also ensured widespread access to treatment for diagnosed individuals, thereby driving revenue growth in the market.
   
• Additionally, Japan's advanced healthcare infrastructure ensures universal coverage, providing HIV patients with affordable and effective treatments. Significant investments in state-of-the-art diagnostic tools, modern treatment facilities, and highly skilled medical professionals position Japan as a leader in managing chronic diseases, including HIV.
   

Saudi Arabia's human immunodeficiency virus therapeutics market is expected to witness substantial growth during the forecast period.
 

• Saudi Arabia has undertaken extensive public health campaigns to raise awareness about HIV transmission and prevention. According to December 2023 data from the Government of Saudi Arabia, the nation has launched the Saudi Initiative to Combat AIDS in GCC Countries, aiming to bolster health support efforts against HIV in the Gulf region. Such government initiatives are expected to drive significant awareness related to HIV, contributing to the market growth in the country.
   
• Further, Government of Saudi Arabia has made significant investments in its healthcare system, which is publicly funded through the Saudi Ministry of Health. This includes substantial resources directed toward HIV prevention, treatment, and education. According to The Global Fund (TGF), Saudi Arabia's substantial support for the Global Fund has significantly advanced efforts to combat HIV. In 2022, for the Global Fund's seventh replenishment, Saudi Arabia committed USD 39 million, reflecting a 30% increase from its USD 30 million pledge in 2019 for the sixth replenishment.